Information current as at: 1 September 2022

PBAC meeting date: March 2021
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Venclexta®
Pharmaceutical company:
Abbvie Pty Ltd
(therapeutic use)
  • Acute myeloid leukaemia (AML)
PBAC Submission type:
Change to listing (Major Submission)
Related medicines:

Progress Details

Submission received for:
March 2021 PBAC meeting
Opportunity for consumer comment:
Open 23/12/2020 and close 10/02/2021 (see PBS Website)
PBAC meeting:
Held on 10/03/2021
PBAC outcome published:
Not Recommended (see PBAC Outcomes)
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable

Case ID: a326

Page last updated: 31 August 2022